文献速递免疫规划卫生政策与健康促进

疫苗与生物制品安全性生物标志物研讨会报告

Safety biomarkers for development of vaccines and biologics: Report from the safety biomarkers symposium held on November 28-29, 2017, Marcy l'Etoile, France.
PubMed 文献 · Vaccine · 2020-11-10

会议强调系统生物学、单细胞微流控、下一代动物模型、计算机模拟机器学习分析及体外MIMIC®系统在预测反应原性和免疫炎症反应中的价值,并呼吁机构与产业合作开发更准确可靠的生物标志物以支持研发决策。

要点

  • 系统生物学结合单细胞微流控可改善疫苗与佐剂制剂的反应原性和安全性预测。
  • 需建立更接近目标人群的下一代动物模型及注射部位局部反应原性可接受性标准。
  • 体外MIMIC®系统可辅助评估生物制品与疫苗的免疫毒性、免疫原性和作用机制。

核心结论

  • 机构和产业组织应合作开发预测疫苗与生物制品反应原性和免疫炎症反应的工具与方法,并开发更准确可靠的 sécurité 生物标志物以支持研发决策。

主要发现

  • 系统生物学方法结合单细胞微流控应用于临床前与临床转化研究,可改善反应原性和安全性预测。
  • 需要评估更接近目标人群的下一代动物模型及临床前动物种属注射部位局部反应原性可接受性标准。
  • 需要先进的基于机器学习计算机模拟分析、种属特异性细胞或组织表达、受体占据与动力学及基于细胞的功能活性试验来改善生物制品临床前安全性评估。
  • 体外MIMIC®系统可用于辅助评估生物制品与疫苗的免疫毒性、免疫原性、免疫炎症及作用机制。

临床怎么用

  • 在疫苗与生物制品研发早期识别潜在安全性问题,以降低投资风险。
  • 利用系统生物学、单细胞微流控、计算机模拟分析和体外MIMIC®系统等工具预测反应原性和免疫炎症反应。
  • 通过更准确可靠的生物标志物为疫苗与生物制品的淘汰或推进决策提供依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccines prevent infectious diseases, but vaccination is not without risk and adverse events are reported although they are more commonly reported for biologicals than for vaccines. Vaccines and biologicals must undergo vigorous assessment before and after licensure to minimise safety concerns. Potential safety concerns should be identified as early as possible during the development for vaccines and biologicals to minimize investment risk. State-of-the art tools and methods to identify safety concerns and biomarkers that are predictive of clinical outcomes are indispensable. For vaccines and adjuvant formulations, systems biology approaches, supported by single-cell microfluidics applied to translational studies between preclinical and clinical studies, could improve reactogenicity and safety predictions. Next-generation animal models for clinical assessment of injection-site reactions with greater relevance for target human population and criteria to define the level of acceptability of local reactogenicity at vaccine injection sites in pre-clinical animal species should be assessed. Advanced in silico machine-learning-based analytics, species-specific cell or tissue expression, receptor occupancy and kinetics and cell-based assays for functional activity are needed to improve pre-clinical safety assessment of biologicals. The in vitro MIMIC® system could be used to compliment preclinical and clinical studies for assessing immune-toxicity, immunogenicity, immuno-inflammatory and mode of action of biologicals and vaccines. Sanofi Pasteur brought together leading experts in this field to review the state-of-the-art at a unique 'Safety Biomarkers Symposium' on 28-29 November 2017. Here we summarise the proceedings of this symposium. This unique scientific meeting confirmed the importance for institutions and industrial organizations to collaborate to develop tools and methods needed for predicting reactogenicity and immune-inflammatory reactions to vaccines and biologicals, and to develop more accuracy, reliability safety biomarkers, to inform decisions on the attrition or advancement of vaccines and biologicals.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Doubovetzky M, Ataman-Önal Y, Chousterman B, et al. Safety biomarkers for development of vaccines and biologics: Report from the safety biomarkers symposium held on November 28-29, 2017, Marcy l'Etoile, France. Vaccine. 2020. PMID: 33187767. doi:10.1016/j.vaccine.2020.10.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。